Preface

The central message up front: rapamycin (sirolimus) has the most robust and reproducible lifespan-extension data of any pharmacological agent in animal models, but human evidence in healthy ageing is confined to small, short-to-medium term RCTs and surrogate/biomarker endpoints — no human data demonstrate reductions in mortality, major morbidity, or extension of healthspan/lifespan.[1][2][3][4] All use for longevity is off-label.



1. Scope

– Full title: Clinical Knowledge Summary: Rapamycin (Longevity Medicine).

– Covered: Off-label/low-dose intermittent oral rapamycin (sirolimus) and rapalogs (everolimus) used in adults seeking geroprotection/healthspan extension; patient selection, baseline work-up, dosing regimens reported in human trials, monitoring, safety and practical scenarios.

– Not covered: On-label indications (transplant immunosuppression, mTOR-driven malignancy, TSC/LAM, drug-eluting stents); paediatric use; topical rapamycin for dermatological/vascular anomalies; preclinical rationale is confined to a clearly marked subsection.

– Positioning: Adjunctive to — never a substitute for — guideline-based conventional primary and secondary care (statins, antihypertensives, glycaemic control, exercise, smoking cessation). Content is intended for use within a shared-decision, informed-consent framework, ideally within trials or registries.



2. Background and pathophysiology

– mTOR biology: mTOR is a nutrient-sensing kinase forming two complexes. mTORC1 (amino-acid sensitive) drives protein synthesis and anabolism; its inhibition increases autophagy. mTORC2 governs glucose metabolism and, when inhibited, produces insulin resistance and immunosuppression. Rapamycin is an allosteric mTORC1 inhibitor; mTORC2 is inhibited only after prolonged/continuous exposure — the mechanistic basis for intermittent, low-dose regimens intended to preserve benefit while sparing metabolic/immune harm.[5][6]

– Rationale for ageing: mTORC1 inhibition mimics the nutrient-sensing effects of caloric restriction, activating autophagy and enhancing resilience mechanisms of ageing. Rapamycin is classed as a senomorphic — it suppresses the senescence-associated secretory phenotype (SASP) rather than clearing senescent cells.[1][7][8]

– Most robust human mechanistic evidence:

– Immune/vaccine function: Selective mTOR inhibition (everolimus/RTB101) improved influenza vaccination antibody responses and reduced self-reported infections in older adults — the most clinically-oriented human mechanistic signal.[5]

– Genome/senescence markers: A placebo-controlled experimental-medicine study in older adults found low-dose rapamycin significantly reduced immune-cell p21 (a DNA-damage-induced senescence marker).[9]

– Epigenetic ageing: Rapamycin retarded epigenetic ageing of human keratinocytes in vitro — mechanistically interesting but not demonstrated to alter clinical outcomes.[10]

– Preclinical only (mechanistic plausibility, not human evidence): Dose-dependent median lifespan extension of up to 23–26% in mice (effective even when started in late midlife); delayed age-related cardiac, renal, cognitive, immune and tendon decline; improved cardiac function in companion dogs. These data underpin interest but do not establish human benefit.[1][8]



3. Evidence base and grading

Available human evidence comprises: one systematic review (19 heterogeneous studies); several small-to-medium RCTs (Kraig 2018 n=25; PEARL n≈115; everolimus vaccine trial n=218; RTB101 trials); and an off-label observational survey cohort (n=333).[2][5][11][3][12] Endpoints are predominantly surrogate/biomarker or self-reported; no RCT has assessed mortality, incident cardiovascular disease, cancer, dementia, or functional independence as primary outcomes.

The figure below, from Mannick & Lamming (Nature Aging, 2023), summarises how dosing regimen determines the balance of benefit versus metabolic harm across humans and mice — the central practical concept.

Figure 3 The known and unknown effects of rapalog-dosing regimens on metabolic health, the immune system, healthspan and longevity in humans and mice. Chronic (daily) dosing of rapamycin is associated with impaired blood glucose regulation and hyperlipidemia in humans and mice, while everolimus in mice has somewhat reduced effects on glucose homeostasis. Intermittent or low-dose regimens of rapamycin or everolimus are associated with reduced side effects, while the mTORC1-selective rapalog DL001 does not impair blood glucose control or alter circulating lipid levels. Blue up arrow, improvement; red down arrow, impairment; dash indicates no change; question mark indicates unknown.

GRADE-style certainty and recommendation for each major outcome:

Outcome	Evidence statement	Certainty (GRADE)	Recommendation	Key limitations
All-cause mortality / lifespan	No human data; extrapolated from rodent ITP only	Very low	Only in research	Indirectness (animal), no human outcome data [1], [2]
Healthspan / functional status (strength, gait, frailty)	Small RCTs underpowered; PEARL showed improved lean mass and reduced pain in women at 10 mg/week; no consistent performance gains	Low	Conditional / only in research	Imprecision, inconsistency, self-report [3], [11]
Immune function / infection reduction	Everolimus/RTB101 RCTs improved vaccine response and reduced infections; RTB101 monotherapy negative in n=1024 trial	Moderate (rapalogs)	Conditional (rapalogs; not directly rapamycin)	Indirectness (rapalog vs sirolimus), inconsistency [5]
Safety of low-dose intermittent use (short–medium term)	Multiple small RCTs + survey: AEs similar to placebo over ≤48 weeks	Low–Moderate	Conditional (short-term safety)	Short duration, small n, no long-term data [3], [11][12]
Ageing biomarkers (p21, epigenetic clocks, SASP)	Reductions shown in vitro / small studies	Low	Only in research	Surrogate not linked to clinical benefit [9], [10]
Cardiometabolic / visceral adiposity	PEARL: no change in visceral fat; biomarkers within normal range	Low	Recommend against for this indication	Null primary outcome [3]

– Publication bias: likely — strong industry/commercial and enthusiast interest, many small positive surrogate studies, and a large formally-neutral survey cohort.[12][4]

– Overarching statement: Do not infer hard clinical benefit (reduced mortality/morbidity) from the available surrogate data — that linkage is not supported.[2][4]



4. Patient selection and indications

– Regulatory/ethical status: Rapamycin/sirolimus is licensed (MHRA/FDA/EMA) only for transplant, TSC-LAM and oncology indications. All longevity use is off-label, unlicensed for this purpose, and should be framed as adjunctive care with explicit informed consent, or preferably within a trial/registry. Document that no regulatory body endorses this indication.[4]

– Who might be considered (expert-consensus/mechanistic, not guideline-based):

– Middle-aged to older adults (broadly ≥50) in good general health seeking geroprotection, who understand the experimental nature.

– Those with features of immunosenescence or high age-related disease risk where the immune/senescence rationale is strongest.[5][9]

– Candidates able to adhere to monitoring and who are not in high-infection-risk settings.

– Exclusion / high-risk groups (avoid or specialist input only):

– Active infection, immunodeficiency, or high infection exposure.

– Poorly controlled diabetes, dyslipidaemia, or metabolic syndrome (rapamycin can worsen glucose/lipids, especially at higher/continuous doses).[7][2]

– Planned surgery or active wound healing (impaired wound healing, mouth ulcers).[5]

– Interstitial lung disease, significant cytopenias, uncontrolled hepatic/renal impairment.

– Pregnancy, breastfeeding, or planning conception (see §7).

– Frail older adults with multimorbidity/polypharmacy — benefit–harm balance unfavourable; only within research.

– Concurrent CYP3A4/P-gp interacting drugs (see §7).

– Athletic/anabolic goals: mTORC1 inhibition opposes muscle protein synthesis; rapamycin is not appropriate for those primarily seeking hypertrophy/performance (mechanistic caution).[6]



5. Assessment and baseline work-up

– History & examination: full medication/supplement review (CYP3A4/P-gp), infection risk, surgical/wound status, metabolic and cardiovascular risk, reproductive plans; frailty assessment in older adults; baseline oral mucosa and skin exam.

– Baseline investigations:

– FBC (baseline cytopenias — rapamycin lowered haemoglobin, haematocrit, RBC, MCV in the Kraig RCT).[11]

– Fasting lipids and HbA1c/fasting glucose (± OGTT if metabolically at risk) — monitor for dyslipidaemia/hyperglycaemia.[7][2]

– Renal and liver function.

– Fasting glucose/insulin for insulin sensitivity if concerned.

– Consider baseline sirolimus trough level capability if using higher/continuous dosing (not routinely needed for weekly low-dose).

– Optional ageing biomarkers (research/monitoring context only — do not use to justify clinical benefit): epigenetic clock, hsCRP/IL-6 (inflammaging), DXA for lean mass/visceral fat (PEARL primary tool), grip strength, gait speed, 30-second chair-stand, 6-minute walk.[6][3]

– Risk stratification: low risk = healthy, no metabolic disease, no interacting drugs, low infection exposure; moderate = controlled metabolic disease or age ≥70; high = frailty, immunocompromise, uncontrolled metabolic disease, upcoming surgery — high-risk groups should generally not be offered treatment outside research.



6. Dosing regimens and practical implementation

There is no established or validated longevity dose; the ACCP notes the absence of formal dosing guidance.[4] Regimens below are those used in human trials, given as descriptive reference, not endorsement.

– Regimens with supporting (short-term) human data:

– Intermittent weekly oral rapamycin 5–6 mg once weekly — used in RAPA-EX-01 and PEARL; expected to partially inhibit mTORC1 (S6K1 suppression ≥5–7 days) while sparing mTORC2.[6][3]

– PEARL trial: 5 mg or 10 mg weekly over 48 weeks; AEs similar to placebo; 10 mg/week associated with improved lean mass and reduced pain in women.[3]

– Everolimus 0.5 mg daily or 5 mg weekly × 6 weeks improved vaccine response (rapalog data, not sirolimus).[5]

– Low daily dosing 1 mg/day was safe short-term in a small RCT of adults aged 70–95 but produced red-cell parameter decrements.[11]

– Dose–response principle: metabolic harm (hyperglycaemia, dyslipidaemia, insulin resistance) is driven by chronic/continuous, higher-dose exposure that engages mTORC2; intermittent low-dose regimens minimise this. Immunosuppressant/oncology doses are 10–80× higher than putative geroprotective doses.[7][13][1]

– Practical approach (expert-consensus/pragmatic): start at the lowest studied weekly dose, take on a fixed weekly day, consistent relative to food (bioavailability variable; be consistent), reassess at 6–12 weeks. Titration and any use above weekly low-dose require specialist oversight and therapeutic drug monitoring.

– Caution flag: regimens beyond weekly 5–10 mg, daily dosing, or combination “stacks” are extrapolated beyond the short-term human safety data and require caution.



7. Monitoring, safety and follow-up

– Monitoring plan:

– Clinical: oral ulcers/stomatitis, skin rash/acneiform eruption, GI symptoms, wound healing, signs of infection, oedema.

– Laboratory: FBC, fasting lipids, HbA1c/fasting glucose, renal and liver function. Consider sirolimus trough levels if daily/higher dosing.

– Ageing biomarkers (optional, research): as in §5 — for tracking only.

– Timepoints (pragmatic/expert-consensus): baseline → 6–12 weeks (bloods, tolerability) → 6 months → 12 months and annually thereafter. Any new symptoms prompt earlier review.

– Adverse effects:

– Common (dose-dependent): mouth ulcers/stomatitis, acneiform rash, GI upset; mild red-cell parameter decrements (Hb, Hct, MCV). In healthy cohorts on low-dose intermittent regimens, AEs were comparable to placebo over ≤48 weeks.[11][3][12]

– Metabolic (higher/continuous dosing): hyperglycaemia, hypertriglyceridaemia, raised LDL/total cholesterol, insulin resistance — more prominent in patients with existing age-related disease.[7][2]

– Serious but uncommon: infection (immunosuppression), impaired wound healing, cytopenias, interstitial pneumonitis, mouth ulceration severe enough to limit intake, peripheral oedema. Pneumonitis and significant cytopenias are class effects primarily at higher doses.

– Actions for abnormalities: worsening lipids/glucose → intensify lifestyle/pharmacological metabolic management or reduce/stop; significant cytopenia, pneumonitis, or serious infection → stop and refer; troublesome stomatitis → dose reduction or hold; hold peri-operatively (typically pause around surgery/wounds given healing impairment).

– Interactions: metabolised by CYP3A4 and P-glycoprotein — avoid or monitor with strong CYP3A4 inhibitors (azole antifungals, macrolides, diltiazem, verapamil, grapefruit) and inducers (rifampicin, carbamazepine, St John’s Wort); additive immunosuppression with other immunosuppressants; caution with statins (myopathy/lipid interplay) and live vaccines.

– Special populations: Pregnancy/breastfeeding — avoid (contraindicated; effective contraception advised for both sexes per label). Renal/hepatic impairment — caution, dose adjustment and specialist input. Frailty/extremes of age — unfavourable benefit–harm; research settings only.



8. Contraindications and cautions

– Absolute: pregnancy and breastfeeding; hypersensitivity to sirolimus; active serious/uncontrolled infection; significant active immunodeficiency; concurrent live vaccine administration (relative-to-absolute depending on timing).

– Relative (specialist advice): poorly controlled diabetes or dyslipidaemia; planned surgery/active wounds; interstitial lung disease; baseline cytopenias; hepatic/renal impairment; frailty/multimorbidity; potent CYP3A4/P-gp interacting medication.

– Harm likely to outweigh benefit with current evidence: frail older adults with multimorbidity; individuals seeking muscle hypertrophy/performance; anyone unable to engage with monitoring or informed consent; use to “improve” a surrogate biomarker in the absence of demonstrated clinical benefit.[2][4]



9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors.

Recommendation: Avoid / restrict to research as a geroprotective agent. Rapamycin can worsen glucose and lipids, and PEARL showed no visceral adiposity benefit.[3][7]

– Assessment: optimise guideline-based cardiometabolic care first (statin, BP control, glycaemic management, exercise, diet).

– Shared decision-making: explain off-label status, absence of outcome data, and metabolic risk.[4]

– If pursued in a research/consent framework: lowest weekly dose, intensive lipid/glucose monitoring at 6–12 weeks.

– Stop criteria: any deterioration in glycaemia/lipids not offset by clear benefit.

Scenario B — Older, frail patient with multimorbidity.

Recommendation: Recommend against outside research. Infection, cytopenia, wound-healing and polypharmacy interaction risks outweigh unproven benefit.[11][4]

– Assessment: frailty, infection risk, medication interactions, wound/surgical status.

– Management: prioritise proven interventions (exercise, nutrition, deprescribing, vaccination). If immune/vaccine benefit is the goal, note that the supporting data are for rapalogs (everolimus/RTB101), not sirolimus.[5]

Scenario C — Healthy older adult seeking geroprotection, already under specialist care for a stable condition.

Recommendation: Consider (conditional) only within informed-consent adjunctive framework or trial, with the treating specialist informed.

– Assessment: confirm stability, no interacting drugs, no infection/surgery pending; baseline bloods and optional biomarkers.

– Consent: explicit off-label, unproven-clinical-benefit, short-term-only safety data.[3][4]

– Initiation: weekly low-dose (5 mg) intermittent regimen.[6][3]

– Monitoring: 6–12 weeks then 6-monthly (FBC, lipids, glucose, LFT/renal).

– Escalate/stop: serious infection, pneumonitis, significant cytopenia, worsening metabolic profile, or need for surgery → hold/stop and refer.

Scenario D — Patient requesting immune “boosting” ahead of infection season.

Recommendation: Only in research / consider a rapalog signal cautiously. The strongest human immune data are for everolimus/RTB101, and a large RTB101 trial was negative — signal is inconsistent.[5] Prioritise vaccination.



10. Research gaps and future directions

– No human outcome data: mortality, incident CVD, cancer, dementia, frailty and functional independence remain untested — the paramount gap.[1][2][4]

– Optimal dose and schedule: the cadence balancing autophagy activation against anabolic/metabolic harm is unknown; weekly 5–10 mg is pragmatic but unvalidated for outcomes.[6][3]

– Long-term safety: no data beyond ~48 weeks in healthy cohorts; cumulative metabolic, immune and infection risk unquantified.[3][2]

– Biomarker-to-outcome linkage: whether reductions in p21, epigenetic age or SASP translate to clinical benefit is unestablished.[9][10]

– Population specificity: sex differences (PEARL benefits seen in women), frailty, and cardiometabolic subgroups need dedicated study.[3]

– Agent selection: whether mTORC1-selective rapalogs (everolimus, DL001) offer a better therapeutic index than sirolimus.[5][13]

– Where practice should sit: current use should ideally be confined to well-designed RCTs and prospective registries to build the safety/efficacy/dosing base the ACCP identifies as lacking.[4]

References

1. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
2. Targeting Ageing With Rapamycin and Its Derivatives in Humans: A Systematic Review. Lee DJW, Hodzic Kuerec A, Maier AB. The Lancet. Healthy Longevity. 2024;5(2):e152-e162. doi:10.1016/S2666-7568(23)00258-1.
3. Influence of Rapamycin on Safety and Healthspan Metrics After One Year: PEARL Trial Results. Moel M, Harinath G, Lee V, et al. Aging. 2025;17(4):908-936. doi:10.18632/aging.206235.
4. Risks and Benefits for Sirolimus in Aging Prevention. S M, M N K, A K G, et al. Journal of Clinical Pharmacology. 2025;. doi:10.1002/jcph.70112.
5. Geroscience. Kritchevsky SB, Cummings SR. JAMA. 2025;334(12):1094-1102. doi:10.1001/jama.2025.11289.
6. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial. Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(2):e70274. doi:10.1002/jcsm.70274.
7. Biological Versus Chronological Aging: JACC Focus Seminar. Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V. Journal of the American College of Cardiology. 2020;75(8):919-930. doi:10.1016/j.jacc.2019.11.062.
8. Cellular Senescence, Inflammaging and Cardiovascular Disease. Zanders L, Arifaj D, Wagner JUG, Dimmeler S. Immunological Reviews. 2026;337(1):e70084. doi:10.1111/imr.70084.
9. Rapamycin Exerts Its Geroprotective Effects in the Ageing Human Immune System by Enhancing Resilience Against DNA Damage. Kell L, Jones EJ, Gharahdaghi N, et al. Aging Cell. 2026;25(2):e70364. doi:10.1111/acel.70364.
10. Rapamycin Retards Epigenetic Ageing of Keratinocytes Independently of Its Effects on Replicative Senescence, Proliferation and Differentiation. Horvath S, Lu AT, Cohen H, Raj K. Aging. 2019;11(10):3238-3249. doi:10.18632/aging.101976.
11. A Randomized Control Trial to Establish the Feasibility and Safety of Rapamycin Treatment in an Older Human Cohort: Immunological, Physical Performance, and Cognitive Effects. Kraig E, Linehan LA, Liang H, et al. Experimental Gerontology. 2018;105:53-69. doi:10.1016/j.exger.2017.12.026.
12. Evaluation of Off-Label Rapamycin Use to Promote Healthspan in 333 Adults. Kaeberlein TL, Green AS, Haddad G, et al. GeroScience. 2023;45(5):2757-2768. doi:10.1007/s11357-023-00818-1.
13. Targeting the biology of aging with mTOR inhibitors. Mannick JB, Lamming DW. Nature Aging. 2023;3(6):642-660. doi:10.1038/s43587-023-00416-y.